Published in Arch Neurol on October 01, 2008
Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain (2009) 5.03
Neuronal autoantigens--pathogenesis, associated disorders and antibody testing. Nat Rev Neurol (2012) 3.20
Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol (2011) 2.99
IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment. Neurology (2012) 2.78
Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology (2011) 2.57
Determination of neuronal antibodies in suspected and definite Creutzfeldt-Jakob disease. JAMA Neurol (2014) 2.56
Diffusion-weighted MRI hyperintensity patterns differentiate CJD from other rapid dementias. Neurology (2011) 2.42
Antibodies and neuronal autoimmune disorders of the CNS. J Neurol (2009) 2.40
Chronic pain as a manifestation of potassium channel-complex autoimmunity. Neurology (2012) 2.00
Adult-onset drug-refractory seizure disorder associated with anti-voltage-gated potassium-channel antibody. Epilepsia (2009) 1.88
Treatable neurological disorders misdiagnosed as Creutzfeldt-Jakob disease. Ann Neurol (2011) 1.86
Autoimmune dementia: clinical course and predictors of immunotherapy response. Mayo Clin Proc (2010) 1.85
Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping. JAMA Neurol (2013) 1.78
Autoimmune encephalopathies. Ann N Y Acad Sci (2014) 1.65
The evaluation of rapidly progressive dementia. Neurologist (2011) 1.30
NMDA receptor autoantibodies in sporadic Creutzfeldt-Jakob disease. J Neurol (2012) 1.21
Voltage-gated potassium channel complex antibodies in Creutzfeldt-Jakob disease. J Neurol (2012) 1.17
Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies. Eur J Neurosci (2010) 1.13
Cell-surface central nervous system autoantibodies: clinical relevance and emerging paradigms. Ann Neurol (2014) 1.08
Paraneoplastic and other autoimmune disorders of the central nervous system. Neurohospitalist (2013) 0.97
Neuronal antibodies in patients with suspected or confirmed sporadic Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry (2014) 0.92
Anti-LGI1-associated cognitive impairment: Presentation and long-term outcome. Neurology (2016) 0.91
Peripherin-IgG association with neurologic and endocrine autoimmunity. J Autoimmun (2010) 0.91
Effect of rituximab in patients with leucine-rich, glioma-inactivated 1 antibody-associated encephalopathy. JAMA Neurol (2014) 0.88
More than memory impairment in voltage-gated potassium channel complex encephalopathy. Eur J Neurol (2014) 0.86
Pathologically confirmed autoimmune encephalitis in suspected Creutzfeldt-Jakob disease. Neurol Neuroimmunol Neuroinflamm (2015) 0.85
Ethics in prion disease. Prog Neurobiol (2013) 0.83
Immunologically mediated dementias. Curr Neurol Neurosci Rep (2009) 0.83
Diagnosis and treatment of rapidly progressive dementias. Neurol Clin Pract (2012) 0.83
Presence of voltage-gated potassium channel complex antibody in a case of genetic prion disease. BMJ Case Rep (2014) 0.81
Autoimmune Encephalitis. Eur Neurol Rev (2013) 0.80
Comparing CSF biomarkers and brain MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease. Neurol Clin Pract (2015) 0.80
Gerstmann-Straüssler-Scheinker disease: novel PRNP mutation and VGKC-complex antibodies. Neurology (2014) 0.80
Reversible symmetrical external capsule hyperintensity as an early finding of autoimmune encephalitis. Neurol Sci (2014) 0.78
Detection of anti-glutamate receptor ε2 and anti-N-methyl-D: -aspartate receptor antibodies in a patient with sporadic Creutzfeldt-Jakob disease. J Neurol (2011) 0.78
Metabolic disorders with clinical and radiologic features of sporadic Creutzfeldt-Jakob disease. Neurol Clin Pract (2015) 0.76
Autoimmune encephalitis mimicking Creutzfeldt-Jakob disease. Neurol Clin Pract (2014) 0.75
Case Studies Illustrating Focal Alzheimer's, Fluent Aphasia, Late-Onset Memory Loss, and Rapid Dementia. Neurol Clin (2016) 0.75
LGI1 antibody encephalopathy overlapping with sporadic Creutzfeldt-Jakob disease. Neurol Neuroimmunol Neuroinflamm (2016) 0.75
Treating seizures and preventing amnesia in LGI1-antibody encephalitis: A new MRI signature? Neurol Neuroimmunol Neuroinflamm (2015) 0.75
Wait and see: a 5 year history of 'recurrent dementia'. BMJ Case Rep (2014) 0.75
Immunotherapy responsive autoimmune subacute encephalitis: a report of two cases. Case Rep Med (2010) 0.75
Creutzfeldt-Jakob disease mimicking autoimmune encephalitis with CASPR2 antibodies. BMC Neurol (2014) 0.75
Two Unique Cases with Anti-GluR Antibody-Positive Encephalitis. Clin Med Insights Case Rep (2013) 0.75
Creutzfeldt-Jakob Disease-Like Periodic Sharp Wave Complexes in Voltage-Gated Potassium Channel-Complex Antibodies Encephalitis: A Case Report. J Clin Neurophysiol (2016) 0.75
Prion-specific and surrogate CSF biomarkers in Creutzfeldt-Jakob disease: diagnostic accuracy in relation to molecular subtypes and analysis of neuropathological correlates of p-tau and Aβ42 levels. Acta Neuropathol (2017) 0.75
Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain (2004) 7.38
Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology (2004) 4.74
Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology (2008) 4.31
Diffusion-weighted and fluid-attenuated inversion recovery imaging in Creutzfeldt-Jakob disease: high sensitivity and specificity for diagnosis. AJNR Am J Neuroradiol (2005) 3.11
Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol (2001) 3.06
Diffusion-weighted MRI abnormalities as an early diagnostic marker for Creutzfeldt-Jakob disease. Neurology (2004) 2.76
Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med (1995) 2.32
CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology (2006) 2.19
Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol (1997) 2.17
EEG in Creutzfeldt-Jakob disease. Clin Neurophysiol (2006) 2.08
Creutzfeldt-Jakob disease: clinical analysis of a consecutive series of 230 neuropathologically verified cases. Ann Neurol (1986) 2.06
Misleading results with the 14-3-3 assay for the diagnosis of Creutzfeldt-Jakob disease. Neurology (2000) 1.82
How to improve the clinical diagnosis of Creutzfeldt-Jakob disease. Brain (1999) 1.71
Rapidly progressive dementia. Neurol Clin (2007) 1.58
Potassium channel antibody associated encephalopathy presenting with a frontotemporal dementia like syndrome. Arch Neurol (2007) 1.48
Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc (2006) 1.46
New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol (2000) 1.38
Sporadic Creutzfeldt-Jakob disease in the United Kingdom: analysis of epidemiological surveillance data for 1970-96. BMJ (1997) 1.27
Ion channel and striational antibodies define a continuum of autoimmune neuromuscular hyperexcitability. Muscle Nerve (2002) 1.13
Early evolution and incidence of electroencephalographic abnormalities in Creutzfeldt-Jakob disease. J Clin Neurophysiol (1986) 1.11
Unilateral Creutzfeldt-Jakob disease. Neurology (1986) 1.08
Morvan's syndrome associated with voltage-gated K+ channel antibodies. Neurology (2000) 1.07
Emerging pharmacotherapies for Creutzfeldt-Jakob disease. Arch Neurol (2006) 1.01
Clinical and genetic features of human prion diseases in Catalonia: 1993-2002. Eur J Neurol (2004) 0.96
Thymoma-associated neuromyotonia with antibodies against voltage-gated potassium channels presenting as chronic intestinal pseudo-obstruction. Eur Neurol (2005) 0.95
[Creutzfeldt-Jakob disease, Heidenhain variant: case report with MRI (DWI) findings]. Arq Neuropsiquiatr (2004) 0.87
Neuromyotonia: autoimmune pathogenesis and response to immune modulating therapy. J Neurol Sci (2000) 0.84
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (2004) 13.18
The spectrum of neuromyelitis optica. Lancet Neurol (2007) 11.83
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med (2005) 10.39
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain (2007) 4.50
Brain abnormalities in neuromyelitis optica. Arch Neurol (2006) 4.28
Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol (2008) 3.95
Postural orthostatic tachycardia syndrome: the Mayo clinic experience. Mayo Clin Proc (2007) 3.32
Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol (2006) 3.26
Rapidly progressive dementia. Ann Neurol (2008) 3.00
Adult-onset opsoclonus-myoclonus syndrome. Arch Neurol (2012) 2.95
Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol (2004) 2.91
National Stroke Association guidelines for the management of transient ischemic attacks. Ann Neurol (2006) 2.82
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol (2006) 2.80
Clinical problem-solving. The eyes have it. N Engl J Med (2012) 2.69
[(18)F]-fluorodeoxyglucose-positron emission tomography in patients with active myelopathy. Mayo Clin Proc (2013) 2.64
Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol (2012) 2.49
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol (2013) 2.46
Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology (2013) 2.34
Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol (2003) 2.29
Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med (2008) 2.26
Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol (2010) 2.26
Scapuloperoneal spinal muscular atrophy and CMT2C are allelic disorders caused by alterations in TRPV4. Nat Genet (2009) 2.21
Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A (2011) 2.11
Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. JAMA Neurol (2013) 2.10
Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc (2003) 2.09
Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol (2007) 2.07
Experimental autoimmune autonomic neuropathy. J Neurophysiol (2003) 2.02
Do not treat from CIS onset: evaluate disease course and prognosis first--yes. Mult Scler (2012) 2.01
Chronic pain as a manifestation of potassium channel-complex autoimmunity. Neurology (2012) 2.00
The spectrum of autoimmune autonomic neuropathies. Ann Neurol (2003) 1.93
Modeling chronic glycemic exposure variables as correlates and predictors of microvascular complications of diabetes. Diabetes Care (2006) 1.93
Autoimmune dementia: clinical course and predictors of immunotherapy response. Mayo Clin Proc (2010) 1.85
Batch effect correction for genome-wide methylation data with Illumina Infinium platform. BMC Med Genomics (2011) 1.84
Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial. Muscle Nerve (2010) 1.82
Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol (2003) 1.79
Passive transfer of autoimmune autonomic neuropathy to mice. J Neurosci (2004) 1.78
Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping. JAMA Neurol (2013) 1.78
Sleep manifestations of voltage-gated potassium channel complex autoimmunity. Arch Neurol (2011) 1.77
An outbreak of neurological autoimmunity with polyradiculoneuropathy in workers exposed to aerosolised porcine neural tissue: a descriptive study. Lancet Neurol (2009) 1.73
Application of the ABCD2 score to identify cerebrovascular causes of dizziness in the emergency department. Stroke (2012) 1.65
Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol (2009) 1.61
Paraneoplastic jaw dystonia and laryngospasm with antineuronal nuclear autoantibody type 2 (anti-Ri). Arch Neurol (2010) 1.60
Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol (2008) 1.59
Rapidly progressive dementia. Neurol Clin (2007) 1.58
Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Arch Neurol (2009) 1.55
Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol (2005) 1.51
Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol (2011) 1.49
Reversible extralimbic paraneoplastic encephalopathies with large abnormalities on magnetic resonance images. Arch Neurol (2009) 1.48
Utility of MRI in spinal arteriovenous fistula. Neurology (2012) 1.46
Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc (2006) 1.46
Striational antibodies in a paraneoplastic context. Muscle Nerve (2013) 1.46
Monotonicity of nerve tests in diabetes: subclinical nerve dysfunction precedes diagnosis of polyneuropathy. Diabetes Care (2005) 1.46
Should there be pediatric neurohospitalists? Neurology (2013) 1.44
Intermittent atrial fibrillation may account for a large proportion of otherwise cryptogenic stroke: a study of 30-day cardiac event monitors. J Stroke Cerebrovasc Dis (2009) 1.43
CSF complements serum for evaluating paraneoplastic antibodies and NMO-IgG. Neurology (2011) 1.41
Epidermal nerve fibers: confidence intervals and continuous measures with nerve conduction. Neurology (2012) 1.41
Organ donation after cardiac death in amyotrophic lateral sclerosis. Ann Neurol (2012) 1.41
Neuronal intracellular transport and neurodegenerative disease. Neurology (2011) 1.41
Severe hypercalcemia following vitamin d supplementation in a patient with multiple sclerosis: a note of caution. Arch Neurol (2012) 1.40
Pearls & oy-sters: the use of CT venography in Hirayama disease. Neurology (2012) 1.40
Pseudopseudoseizures: conditions that may mimic psychogenic non-epileptic seizures. Psychosomatics (2011) 1.39
Diagnostic yield of electroencephalography in a general inpatient population. Mayo Clin Proc (2013) 1.39
Neuromyelitis optica: changing concepts. J Neuroimmunol (2007) 1.39
Post-surgical inflammatory neuropathy. Brain (2010) 1.38
Idiopathic autonomic neuropathy: comparison of cases seropositive and seronegative for ganglionic acetylcholine receptor antibody. Arch Neurol (2004) 1.38
Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol (2002) 1.36
Stiff-man syndrome and variants: clinical course, treatments, and outcomes. Arch Neurol (2012) 1.34
Autoantibody profiles and neurological correlations of thymoma. Clin Cancer Res (2004) 1.33
Imaging features of copper deficiency myelopathy: a study of 25 cases. Neuroradiology (2005) 1.32
Positron emission tomography-computed tomography in paraneoplastic neurologic disorders: systematic analysis and review. Arch Neurol (2010) 1.28
GABAB receptor autoantibody frequency in service serologic evaluation. Neurology (2013) 1.28
Autoimmune gastrointestinal dysmotility treated successfully with pyridostigmine. Gastroenterology (2006) 1.28
Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol (2009) 1.27